Pharmaphorum
Agios is planning to file its sickle cell disease candidate mitapivat with the FDA under the accelerated pathway within the next few months.
Pharmaphorum
Agios is planning to file its sickle cell disease candidate mitapivat with the FDA under the accelerated pathway within the next few months.
Pharmaphorum
Agios is planning to file its sickle cell disease candidate mitapivat with the FDA under the accelerated pathway within the next few months.